The Prognostic Utility of Plasma NGAL Levels in ST Segment Elevation in Myocardial Infarction Patients

Table 4

Angiographic, clinical, and biochemical properties of patients in death and survived groups.

	Death, n = 14	Survived, n = 54	value
Female sex, n (%)	5 (35.7)	7 (13)	0.06
Age, years	73.36 ± 10.59	58.44 ± 14.14	<0.001
DM, n (%)	2 (14.3)	10 (18.5)	0.53
HT, n (%)	9 (64.3)	20 (37)	0.06
DL, n (%)	1 (7.1)	7 (%13)	0.47
Smoking, n (%)	9 (64.3)	42 (77.8)	0.23
Family history of CAD, n (%)	0 (0)	9 (16.7)	0.12
Admission time (hours)	6.35 ± 2.87	4.15 ± 2.84	0.01
Admission SBP (mmHg)	103.57 ± 27.90	117.87 ± 20.27	0.03
Myocardial infarction localization
Anterior wall MI, n (%)	9 (64.3)	16 (29.6)	0.04
Inferior wall MI, n (%)	3 (21.4)	30 (55.6)
Posterolateral wall MI, n (%)	2 (14.3)	8 (14.8)
Primer PCI, n (%)	8 (57.1)	32 (59.3)	0.56
Fibrinolytic administration, n (%)	8 (40.7)	22 (57.1)	0.21
NGAL (ng/ml)	357 (71–694)	120 (9–513)	<0.001
Troponin I (ng/ml)	7.39 (0.30–25.00)	1.05 (0.1–25.00)	0.15
CKMB (ng/ml)	20.49 (3.05–300.00)	12.33 (1.63–380.00)	0.21
CRP (mg/dl)	0.71 (0,05–7.06)	0.52 (0.09–9.59)	0.83
Creatinine (mg/dl)	1.01 ± 0.21	0.85 ± 0.17	0.007
GFR (ml/min)	78.35 ± 22.53	107.46 ± 19.58	<0.001
LDL (mg/dl)	119.25 ± 28.11	125.67 ± 36.32	0.54
HDL (mg/dl)	38.92 ± 10.30	36.06 ± 8.70	0.29
Haemoglobin (mg/dl)	13.70 ± 2.34	15.08 ± 2.19	0.06
Leukocytes (K/uL)	13.06 ± 4.57	12.09 ± 4.45	0.49
Platelets (K/uL)	262 (80–428)	239 (72–485)	0.66
Neutrophils (K/uL)	10.15 ± 4.20	8.73 ± 4.03	0.27
Lymphocytes (K/uL)	1.97 ± 0.82	2.26 ± 1.48	0.50
Neutrophil-to-lymphocyte ratio	5.08 (2.04–10.74)	4.44 (0.56–19.90)	0.38

Significant p values are in bold. CAD, coronary artery disease; CKMB, creatine kinase MB; CRP, C-reactive protein; DL, dyslipidemia; DM, diabetes mellitus; GFR, glomerular filtration rate; HDL, high-density lipoprotein; HT, hypertension; LDL, low-density lipoprotein; MI, myocardial infarction; NGAL, neutrophil gelatinase-associated lipocalin; PCI, percutaneous coronary intervention; SBP, systolic blood pressure.